Literature DB >> 1001344

Enzyme activities in skeletal muscles from patients with peripheral arterial insufficiency.

A C Bylund, J Hammarsten, J Holm, T Scherstén.   

Abstract

The enzyme pattern in gastrocnemius muscle tissue was studied in 39 patients with peripheral arterial insufficiency. Phosphofructokinase and glucose-6-phosphate-dehydrogenase were significantly increased in the skeletal muscles from these patients. The most pronounced changes were found in 3-OH-acyl-CoA-dehydrogenase, citrate synthase, and in cytochrome-c-oxidase. These enzyme activities were increased by 60, 40 and 25 per cent respectively. In patients with claudication as the only symptom, the metabolic capacity was generally increased in skeletal muscles affected by the low blood flow. With increasing severity of arterial insufficiency, all enzyme activities decreased and glycolytic enzymes were affected first. 3-OH-acyl-CoA-dehydrogenase, citrate synthase and cytochrome-c-oxidase activities were still comparatively high in patients with gangrenous foot ulcers, indicating some maintenance of the muscle viability even in situations with very low blood flow.

Entities:  

Mesh:

Year:  1976        PMID: 1001344     DOI: 10.1111/j.1365-2362.1976.tb00538.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  23 in total

1.  Delayed calf muscle phosphocreatine recovery after exercise identifies peripheral arterial disease.

Authors:  David C Isbell; Stuart S Berr; Alicia Y Toledano; Frederick H Epstein; Craig H Meyer; Walter J Rogers; Nancy L Harthun; Klaus D Hagspiel; Arthur Weltman; Christopher M Kramer
Journal:  J Am Coll Cardiol       Date:  2006-05-15       Impact factor: 24.094

2.  Peripheral artery disease, calf skeletal muscle mitochondrial DNA copy number, and functional performance.

Authors:  Mary M McDermott; Charlotte A Peterson; Robert Sufit; Luigi Ferrucci; Jack M Guralnik; Melina R Kibbe; Tamar S Polonsky; Lu Tian; Michael H Criqui; Lihui Zhao; James H Stein; Lingyu Li; Christiaan Leeuwenburgh
Journal:  Vasc Med       Date:  2018-05-08       Impact factor: 3.239

3.  Influence of environmental temperature and energy intake on skeletal muscle respiratory enzymes and morphology.

Authors:  M J Dauncey; D L Ingram
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1988

4.  Myocyte vascular endothelial growth factor is required for exercise-induced skeletal muscle angiogenesis.

Authors:  I Mark Olfert; Richard A Howlett; Peter D Wagner; Ellen C Breen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-08-04       Impact factor: 3.619

5.  Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice.

Authors:  I Mark Olfert; Richard A Howlett; Kechun Tang; Nancy D Dalton; Yusu Gu; Kirk L Peterson; Peter D Wagner; Ellen C Breen
Journal:  J Physiol       Date:  2009-02-23       Impact factor: 5.182

6.  Skeletal myofiber VEGF is essential for the exercise training response in adult mice.

Authors:  Hamid Delavar; Leonardo Nogueira; Peter D Wagner; Michael C Hogan; Daniel Metzger; Ellen C Breen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-02-12       Impact factor: 3.619

7.  Conservative management of acute thrombosis in the superficial femoral artery.

Authors:  P M Walker; W R Tanner; K W Johnston
Journal:  Can Med Assoc J       Date:  1983-08-15       Impact factor: 8.262

8.  Biochemical adaptation in the skeletal muscle of rats depleted of creatine with the substrate analogue beta-guanidinopropionic acid.

Authors:  E A Shoubridge; R A Challiss; D J Hayes; G K Radda
Journal:  Biochem J       Date:  1985-11-15       Impact factor: 3.857

Review 9.  Intermittent claudication: new targets for drug development.

Authors:  Eric P Brass
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

10.  An investigation of arterial insufficiency in the rat hindlimb. Correlation of skeletal muscle bloodflow and glucose utilization in vivo.

Authors:  R A Challiss; D J Hayes; G K Radda
Journal:  Biochem J       Date:  1986-12-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.